At argenx, we are united in our commitment to improve the lives of patients by translating immunology innovations into transformative medicines.
The path to pioneer innovations and advance the understanding of autoimmune disease is best achieved through co-creation with patients and their supporters, and our patient advocacy partners.
Most important to our mission are the people who choose to participate in our clinical trials.
At argenx, we believe participation in a clinical trial within a controlled setting is the most appropriate way to access investigational products.
argenx recognizes that during a clinical trial, some participants may feel they have benefited from the investigational product, yet they do not have access to the product after their participation in the trial has ended because it is not yet approved or commercially available in their country.
When an individual request is received from a clinical trial investigator to continue to provide an investigational product to a patient outside the trial, that is commonly referred to as post-trial access.